Recently, consumers reported that when they were buying plasters for their families on an e-commerce platform, they found that there were photos of academicians such as Zhong Nanshan and Li Lanjuan in the promotional pictures of related products in some stores.
Zhong Nanshan said that he has never endorsed or recommended any products for any merchants, including e-commerce. At the same time, he believes that the illegal use of other people's portraits for commercial endorsements and recommendations will also mislead consumers and infringe on the legitimate rights and interests of consumers. In this regard, he hopes that platforms and merchants can actively deal with this situation as soon as possible, and also hopes that relevant departments will strengthen industry supervision to safeguard the legitimate rights and interests of consumers. The lawyer entrusted by Academician Zhong Nanshan's team said that a lawyer's letter had been sent to the platform and was defending his rights, and the platform told him that it was being processed, but it had not yet been processed.
Analysis of the industrial chain: professional division of labor in each link
From the perspective of the main enterprises in each link of the industrial chain, the representative enterprises of raw materials and health care equipment parts in the upstream of the health care product industry chain mainly include Jiabiyou, Jindawei, Youde Precision, etc.; Midstream health care product companies include Tomson Biohealth, Yangshengtang, Infinitus, etc.; The downstream distribution channels are divided into online and offline channels, offline including Tongrentang, Dashenlin and other hospitals, pharmacies, direct stores, etc., and online e-commerce mainly includes Alibaba, JD.com, etc.
The output of health care products is increasing year by year
There are many participants in China's health care products industry, and from the perspective of the number and scale of industry enterprises, the overall market supply capacity shows a growth trend; From the perspective of China's health care product output, the output of the health care product industry from 2016 to 2022 showed an overall growth trend; According to data from the China Nutrition and Health Care Association, the output of China's health care products market in 2022 will be 787,000 tons, a year-on-year increase of 8.31%, reflecting the improvement of the industry's supply level. On the whole, the market supply level of China's health care products industry has increased year by year.
The market size has been steadily increasing
From the perspective of market size data, the market size of China's health care products market from 2018 to 2022 showed a year-on-year upward trend, reaching 627.2 billion yuan in 2021, a year-on-year increase of 12%; According to preliminary statistics, in 2022, the size of China's health care products market will exceed 690 billion yuan.
Chen Yinjiang, vice president of the China Consumers Association, said that health care products should not be advertised as having therapeutic effects, nor should they use misleading language to mislead consumers into believing that they have therapeutic effects. In addition, in accordance with article 46 of the "Advertising Law of the People's Republic of China", advertisements for medical treatment, medicines, medical devices, pesticides, veterinary drugs, and health foods, as well as other advertisements that laws and administrative regulations provide shall be reviewed, shall be reviewed by the relevant departments before publication;
Prospective Economist APP Information Group
For more research and analysis of this industry, please refer to the "2023-2028 China Health Care Products Industry Market Prospect and Investment Planning Analysis Report" by Qianzhan Industry Research Institute
At the same time, the Prospective Industry Research Institute also provides solutions such as industrial big data, industrial research reports, industrial planning, park planning, industrial investment, industrial mapping, smart investment promotion system, industry status certification, IPO consulting/fundraising feasibility study, IPO working paper consulting, etc. To quote the content of this article in any public information disclosure such as prospectus and annual report, formal authorization from Qianzhan Industry Research Institute is required.
More in-depth industry analysis is available in the [Prospective Economist APP], and you can also communicate and interact with 500+ economists/senior industry researchers.